<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264328</url>
  </required_header>
  <id_info>
    <org_study_id>TTCC-2009-03</org_study_id>
    <nct_id>NCT01264328</nct_id>
  </id_info>
  <brief_title>Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer</brief_title>
  <acronym>VECTITAX</acronym>
  <official_title>&quot;Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trial Form Support S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical hypothesis of this study is that the first-line treatment with the combination&#xD;
      of panitumumab and paclitaxel will provide benefit for patients with metastatic or current&#xD;
      Squamous Cell Carcinoma of the Head and Neck (SCCHN)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Panitumumab, a fully human IgG2 anti-EGFR monoclonal antibody, has shown activity in&#xD;
      preclinical models of SCCHN, and promising activity in refractory SCCHN patients in a phase I&#xD;
      clinical trial. Recently, the investigators also reported encouraging outcomes of&#xD;
      anti-EGFR-paclitaxel combination in a phase II study. On the basis of this background, a&#xD;
      phase II clinical trial (VECTITAX study) was designed with the objective of evaluating the&#xD;
      activity and safety profile of panitumumab in combination with paclitaxel in patients with&#xD;
      recurrent or metastatic SCCHN.&#xD;
&#xD;
      The VECTITAX study was a single arm, open label, multicenter, phase II clinical trial. To be&#xD;
      included patients had to have histologically or cytologically confirmed SCCHN. The current&#xD;
      situation had to be recurrent or metastatic, deemed to be untreatable by surgery or&#xD;
      radiotherapy. No previous systemic antineoplastic therapy for the recurrent/metastatic&#xD;
      disease may have been administered. However, previous chemotherapy was allowed as a part of a&#xD;
      multimodality radical treatment if completed &gt;24 weeks before study entry.&#xD;
&#xD;
      Primary endpoint was confirmed objective response rate (ORR) according to RECIST 1.1 criteria&#xD;
      in the intention-to-treat population (ITT). Tumor assessments were planned to be performed&#xD;
      every two months. Response confirmation was to be assessed not before 4 weeks after a partial&#xD;
      or complete response, or before 6 weeks after a stable disease. Secondary endpoints were&#xD;
      disease control rate, time to response, duration of response, progression-free survival&#xD;
      (PFS), OS, safety profile and QoL through EQ-5D-3L with visual analogic scale (VAS). Quality&#xD;
      of life scores were registered at baseline and every eight weeks thereafter.&#xD;
&#xD;
      Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the&#xD;
      first day and in 30 minutes thereafter (if no infusional reaction was observed) plus&#xD;
      intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour&#xD;
      infusion, until progression or unacceptable toxicity. Panitumumab does not require&#xD;
      prophylactic premedication from the first infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2011</start_date>
  <completion_date type="Actual">September 29, 2014</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the effect of the combination of panitumumab and paclitaxel on objective response rate in first-line treatment of metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response, duration of response, progression free-survival, overall survival.</measure>
    <time_frame>2 years</time_frame>
    <description>Secondary Objectives&#xD;
To assess the disease control rate, time to response, duration of response, progression free-survival and overall survival.&#xD;
To estimate changes in patient-reported outcomes (PRO).&#xD;
To describe the safety profile of the combination of panitumumab and paclitaxel.&#xD;
1.3 Exploratory Objectives:&#xD;
To investigate the effects of genetic variation in cancer genes and drug target genes on subject response to panitumumab and Paclitaxel combination chemotherapy.&#xD;
To investigate the predictive potential of different biomarkers on efficacy and/or safety endpoints.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Panitumumab + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab + paclitaxel</intervention_name>
    <description>Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.</description>
    <arm_group_label>Panitumumab + Paclitaxel</arm_group_label>
    <other_name>Vectibix®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Inform Consent&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Histologically or cytologically confirmed SCCHN&#xD;
&#xD;
          -  Diagnosis of metastatic disease by the investigator and/or recurrent disease&#xD;
             determined to be incurable by surgery or radiotherapy&#xD;
&#xD;
          -  Subjects who have received radiation as primary therapy are eligible if radiation&#xD;
             therapy treatment was completed &gt; 4 weeks prior to inclusion&#xD;
&#xD;
          -  Subjects who have previously received chemotherapy as part of the initial&#xD;
             multimodality treatment for locally advanced disease are eligible if the chemotherapy&#xD;
             was completed &gt; 24 weeks prior to inclusion&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion of ≥ 20 mm using conventional techniques&#xD;
             or ≥10 mm with spiral CT scan. Target lesions must not be chosen from a previously&#xD;
             irradiated field unless there had been documented tumour progression in that lesion&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 at screening&#xD;
&#xD;
          -  Haematological function:&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109 cells/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
          -  Kidney function:&#xD;
&#xD;
             o Adequate renal function with creatinine clearance ≥ 60 mL/min)&#xD;
&#xD;
          -  Liver function:&#xD;
&#xD;
               -  AST ≤ 3 x ULN (if liver metastases, ≤ 5 x ULN)&#xD;
&#xD;
               -  ALT ≤ 3 x ULN (if liver metastases, ≤ 5 x ULN)&#xD;
&#xD;
               -  Bilirubin ≤ 2 x ULN&#xD;
&#xD;
          -  Metabolic function:&#xD;
&#xD;
               -  Magnesium ≥ lower limit of normal,&#xD;
&#xD;
               -  Calcium ≥ lower limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented or symptomatic central nervous system metastases&#xD;
&#xD;
          -  Nasopharyngeal carcinoma&#xD;
&#xD;
          -  History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or&#xD;
             evidence of interstitial lung disease on baseline chest scan&#xD;
&#xD;
          -  History of another primary cancer, except:&#xD;
&#xD;
               -  Curatively treated in situ cervical cancer, or&#xD;
&#xD;
               -  Curatively resected non-melanoma skin cancer or&#xD;
&#xD;
               -  Other primary solid tumour curatively treated with no known active disease&#xD;
                  present and no treatment administered for ≥ 3 years prior to starting the study&#xD;
                  treatment. In that case confirmation of inclusion by the sponsor is required.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease ≤ 1 year prior to starting the study&#xD;
             treatment&#xD;
&#xD;
          -  Pulmonary embolism, deep vein thrombosis, or other significant thromboembolic event ≤&#xD;
             8 weeks prior to starting the study treatment&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy of Grade ≥ 2 based on the CTCAE v3.0&#xD;
&#xD;
          -  Subjects not recovered from all previous acute radiotherapy-related toxicities to ≤&#xD;
             grade 1&#xD;
&#xD;
          -  History of severe skin disorder that in the opinion of the investigator may interfere&#xD;
             with study conduct&#xD;
&#xD;
          -  Known positive test for human immunodeficiency virus (HIV) infection, hepatitis C&#xD;
             virus, acute or chronic hepatitis B infection&#xD;
&#xD;
          -  Active infection requiring systemic treatment or any uncontrolled infection ≤ 14 days&#xD;
             prior to starting the study treatment&#xD;
&#xD;
          -  History of interstitial pneumonia or pulmonary fibrosis or signs of interstitial&#xD;
             pneumonia or pulmonary fibrosis on the baseline chest X-ray.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to panitumumab, or other study medications.&#xD;
&#xD;
          -  Prior anti epidermal growth factor receptor (EGFr) antibody therapy or treatment with&#xD;
             small molecule EGFr inhibitors unless received as part of prior multimodality&#xD;
             treatment and completed &gt; 24 weeks prior to starting the study treatment. In this&#xD;
             case, the investigator should confirm that the subject had not presented any previous&#xD;
             cetuximab-related infusion reaction &gt; grade 2.&#xD;
&#xD;
          -  Subject is currently enrolled in or ≤ 30 days since ending other investigational&#xD;
             device, investigational procedure, or drug study(s), or subject is receiving other&#xD;
             investigational agent(s)&#xD;
&#xD;
          -  Subjects requiring use of immunosuppressive agents, however, corticosteroids are&#xD;
             allowed&#xD;
&#xD;
          -  Man or woman of child-bearing potential who do not consent to use adequate&#xD;
             contraceptive precautions during the course of the study, and for 6 months after the&#xD;
             last study drug administration for women, and 3 months for men.&#xD;
&#xD;
          -  Female subject who is pregnant or breast-feeding, or planning to become pregnant&#xD;
             within 6 months after the end of treatment.&#xD;
&#xD;
          -  Major surgery requiring general anesthesia/ spinal anesthesia and a significant&#xD;
             incision ≤ 28 days or minor surgery ≤ 14 days prior to starting the study treatment.&#xD;
             Subjects must have recovered from surgery-related toxicities.&#xD;
&#xD;
          -  Subjects who do not wish to meet the study requirements or are unable to do so.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Jesús Cruz Hernández, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Martínez Trufero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet de Zaragoza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan José Grau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic i Provincial de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquina Martínez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de las Nieves (Granada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio López Pousa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de la Santa Creu i Sant Pau de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfonso Berrocal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Universitario de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Hitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital 12 de Octubre de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ricardo Mesia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Català d'Oncología. Hospital Duran i Reynals de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elvira del Barco Morillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General Yagüe de Burgos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Hurtado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Hospitalaria de Alcorcón de Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Pastor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital La Fe de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruth Vera García, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Yagüe</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Madrid</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.ttccgrupo.org</url>
    <description>This site would like to expose the activities of the group and at the same time serve as an information and communication tool of this pathology for professionals and patients.</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer, panitumumab, TTCC-2009-03</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

